Frank Runge

Title: Frank Runge: Innovator in Medicinal Chemistry

Introduction: Frank Runge is a notable inventor based in Biberach an der Riß, Germany. He holds a significant patent related to pharmaceutical compounds that have implications in treating various central nervous system diseases. His work showcases his dedication and innovation in the field of medicinal chemistry.

Latest Patents: Frank Runge’s most recent patent focuses on the invention of 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives. This invention relates to compounds that are agonists of GPR52, offering potential therapeutic benefits for diseases affecting the central nervous system, among other ailments. The patent encompasses not only the derivatives themselves but also the processes for preparing pharmaceutical compositions that utilize these compounds as medicaments.

Career Highlights: Throughout his career, Frank Runge has made significant contributions to the pharmaceutical industry. He has worked with recognized companies, including Boehringer Ingelheim International GmbH and Arena Pharmaceuticals, Inc. His experience in these organizations has likely enhanced his understanding and capabilities in drug development and innovation.

Collaborations: Frank Runge has collaborated with reputable companies in the pharmaceutical sector, which have provided him with a solid foundation for his research and development efforts. His time at Boehringer Ingelheim and Arena Pharmaceuticals has positioned him within a network of experts, facilitating advancements in medicinal chemistry.

Conclusion: Frank Runge stands out as an innovator in the field of medicinal chemistry, with his patent on 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives marking a significant contribution to the treatment of central nervous system conditions. His work exemplifies the impact that dedicated inventors can have on medicine and highlights the importance of ongoing research and collaboration within the pharmaceutical industry.